JaxBio Technologies Pioneering a New Era in Cancer Diagnosis with Cutting-Edge Blood Test Innovation
July 18, 2024, 3:36 pm
JaxBio Technologies, a forward-thinking medical diagnostics company headquartered in Netanya, Israel, has recently secured a significant €2.5 million grant from the prestigious European Innovation Council (EIC) Accelerator. This grant marks a pivotal moment in JaxBio's journey towards revolutionizing cancer diagnosis through the development of an innovative blood test that promises to transform the landscape of lung cancer detection and management.
Under the visionary leadership of CEO and Founder Dr. Shahar Zirkin, JaxBio has been at the forefront of leveraging liquid biopsy technology to detect thousands of cancer biomarkers in blood with unparalleled sensitivity and cost-effectiveness. This groundbreaking approach not only streamlines the diagnostic process but also enhances the accuracy of therapy prediction, ultimately leading to better outcomes for patients.
The newly acquired funding will play a crucial role in expanding JaxBio's clinical programs and advancing its diagnostics platform to create a simple, rapid, and highly accurate blood test for lung cancer detection. With the potential for additional blended financing amounting to €18.2 million, JaxBio is poised to make a significant impact in the field of cancer diagnostics, offering a ray of hope to individuals battling this devastating disease.
The 2024 EIC Accelerator initiative, which awarded JaxBio the grant, recognized the company's innovative technology as one of the standout solutions among a competitive pool of applicants from 17 countries. This endorsement further validates JaxBio's commitment to excellence, impact, and risk-taking in the pursuit of world-class, high-impact innovations that have the potential to save lives and transform healthcare as we know it.
Dr. Shahar Zirkin, in response to the grant, expressed his gratitude for the validation of JaxBio's technology and the support it provides in realizing the company's vision of developing a simple, sensitive blood test for early cancer diagnosis. In a global climate where investments in biotechnology are scarce, particularly in Israel, this grant serves as a beacon of hope for JaxBio's ongoing mission to bring life-saving innovations to fruition.
JaxBio's liquid biopsy technology, which has previously received recognition through an EU Horizon Europe Cancer Mission grant, has demonstrated its versatility in identifying cancer-specific biomarkers in blood with unmatched sensitivity and affordability. With ongoing research in cancer, heart disease, and neurological disorders, JaxBio's platform technology holds immense promise in revolutionizing disease diagnosis and treatment across various medical domains.
As JaxBio continues to push the boundaries of medical innovation, the company remains dedicated to developing a simple blood test that offers fast, cost-effective, and highly sensitive diagnosis of cancer and other diseases. By delivering next-day results and empowering healthcare providers and patients with timely, informed decisions, JaxBio is poised to make a lasting impact on the future of healthcare.
In conclusion, JaxBio Technologies' receipt of the €2.5 million grant from the EIC Accelerator represents a significant milestone in the company's quest to redefine cancer diagnosis through cutting-edge blood test innovation. With a steadfast commitment to excellence and a vision for transformative healthcare solutions, JaxBio is set to lead the charge in revolutionizing disease detection and management, ultimately saving lives and shaping a brighter future for all.
Under the visionary leadership of CEO and Founder Dr. Shahar Zirkin, JaxBio has been at the forefront of leveraging liquid biopsy technology to detect thousands of cancer biomarkers in blood with unparalleled sensitivity and cost-effectiveness. This groundbreaking approach not only streamlines the diagnostic process but also enhances the accuracy of therapy prediction, ultimately leading to better outcomes for patients.
The newly acquired funding will play a crucial role in expanding JaxBio's clinical programs and advancing its diagnostics platform to create a simple, rapid, and highly accurate blood test for lung cancer detection. With the potential for additional blended financing amounting to €18.2 million, JaxBio is poised to make a significant impact in the field of cancer diagnostics, offering a ray of hope to individuals battling this devastating disease.
The 2024 EIC Accelerator initiative, which awarded JaxBio the grant, recognized the company's innovative technology as one of the standout solutions among a competitive pool of applicants from 17 countries. This endorsement further validates JaxBio's commitment to excellence, impact, and risk-taking in the pursuit of world-class, high-impact innovations that have the potential to save lives and transform healthcare as we know it.
Dr. Shahar Zirkin, in response to the grant, expressed his gratitude for the validation of JaxBio's technology and the support it provides in realizing the company's vision of developing a simple, sensitive blood test for early cancer diagnosis. In a global climate where investments in biotechnology are scarce, particularly in Israel, this grant serves as a beacon of hope for JaxBio's ongoing mission to bring life-saving innovations to fruition.
JaxBio's liquid biopsy technology, which has previously received recognition through an EU Horizon Europe Cancer Mission grant, has demonstrated its versatility in identifying cancer-specific biomarkers in blood with unmatched sensitivity and affordability. With ongoing research in cancer, heart disease, and neurological disorders, JaxBio's platform technology holds immense promise in revolutionizing disease diagnosis and treatment across various medical domains.
As JaxBio continues to push the boundaries of medical innovation, the company remains dedicated to developing a simple blood test that offers fast, cost-effective, and highly sensitive diagnosis of cancer and other diseases. By delivering next-day results and empowering healthcare providers and patients with timely, informed decisions, JaxBio is poised to make a lasting impact on the future of healthcare.
In conclusion, JaxBio Technologies' receipt of the €2.5 million grant from the EIC Accelerator represents a significant milestone in the company's quest to redefine cancer diagnosis through cutting-edge blood test innovation. With a steadfast commitment to excellence and a vision for transformative healthcare solutions, JaxBio is set to lead the charge in revolutionizing disease detection and management, ultimately saving lives and shaping a brighter future for all.